Cancer Treatment News and Research

RSS

CRI introduces new model of philanthropic investment to improve cancer patient care

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today the launch of the Cancer Vaccine Acceleration Fund (CVAF), a new model of philanthropic investment and academic-industry collaboration established in partnership with the Ludwig Institute for Cancer Research Ltd (LICR) to speed the clinical development of therapeutic cancer vaccines and other immune system-based therapies.

15 Dec 2010

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

ICESP selects Ekahau RTLS for staff tracking solution

Ekahau Inc., the worldwide leader in high performance Wi-Fi-based Real Time Location Systems, today announced that Ekahau RTLS is being utilized as the underlying real-time tracking and bi-directional communications technology for a staff tracking solution at Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira - ICESP, part of the "Sistema FMUSP-HC" system, which is the largest public cancer treatment center in Latin America.

14 Dec 2010

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians are combating a devastating side effect of chemotherapy with an innovative new program -- "Hair to Stay" -- to evaluate devices that could reduce scalp hair loss in breast cancer patients.

14 Dec 2010

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.

14 Dec 2010

Combination of SPECT and CT scans could offer protection against lymphedema in breast cancer patients

With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.

13 Dec 2010

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Weightlifting may help prevent lymphedema following breast cancer treatment

Weightlifting may play a key role in the prevention of the painful limb-swelling condition lymphedema following breast cancer treatment, according to new research from the University of Pennsylvania School of Medicine. Combined with the team's previous findings that the exercise limits a worsening of symptoms among women who already have lymphedema, the new data cements the reversal of long-running advice that breast cancer survivors should avoid lifting anything heavier than five pounds after they finish treatment.

10 Dec 2010

Researchers find new light-activated platinum-based compound to kill cancer cells

When it comes to health care blue lights, are usually most useful on the top of ambulances but now new research led by the University of Warwick has found a way to use blue light to activate what could be a highly potent platinum-based cancer treatment.

10 Dec 2010

NCCN announces new guidelines for patients with multiple myeloma

The National Comprehensive Cancer Network recently announced the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Multiple Myeloma. This new resource is a patient-friendly translation of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma, which physicians use when determining appropriate cancer treatment.

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Weightlifting program does not increase risk of lymphedema in breast cancer survivors

A slowly progressive weight lifting program for breast cancer survivors did not increase their risk of lymphedema (arm swelling and discomfort), according to a study that will appear in the December 22/29 issue of JAMA. The study is being released early online to coincide with its presentation at the San Antonio Breast Cancer Symposium.

9 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the medication are anxious to have the tests. According to a new survey of more than 700 women with breast cancer currently taking tamoxifen, almost 80 percent of respondents would choose to have a genetic test that determines CYP2D6 genotype, yet only 14 percent of these women have been tested. CYP2D6 is an enzyme that influences how well the body processes tamoxifen into its more active form.

7 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

NCI director ignorant of cancer prevention, says coalition

On October 22, 2010, Senator Chuck Grassley, ranking member of the Senate Finance Committee, wrote to Dr. Harold Varmus, who was appointed director of the National Cancer Institute (NCI) by President Obama three months previously. The Senator raised questions on the amount of "sponsored travel," sometimes a dozen or more trips a year and almost exclusively to international conferences paid for by outside organizations or companies, taken in recent years by "numerous NCI employees, notably senior leadership."

4 Dec 2010

Cancer Treatment News and Research

CRI introduces new model of philanthropic investment to improve cancer patient care

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

ICESP selects Ekahau RTLS for staff tracking solution

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

Combination of SPECT and CT scans could offer protection against lymphedema in breast cancer patients

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Depression drug appears effective in reducing pain associated with breast cancer treatment

Weightlifting may help prevent lymphedema following breast cancer treatment

Researchers find new light-activated platinum-based compound to kill cancer cells

NCCN announces new guidelines for patients with multiple myeloma

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Expert discusses androgen deprivation therapy for prostate cancer

Weightlifting program does not increase risk of lymphedema in breast cancer survivors

Immunomedics reports CD22 antibody produced significant anti-tumor response

John Theurer Cancer Center presents research findings at ASH meeting

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

NCI director ignorant of cancer prevention, says coalition

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News